Ian Dardani

Ian Dardani
Occupation	Entrepreneur, bioengineeer
Known for	Co-founder and CEO of Biocartesian
Education	PhD in Bioengineering, University of Pennsylvania; Bioscience Enterprise, University of Cambridge; Villanova University

Ian Dardani is an American entrepreneur and bioengineer who is the co-founder and CEO of Biocartesian, a biotechnology startup that converts biological information into digital molecular maps. The company, which participated in Y Combinator's Summer 2024 batch, combines advanced microscopy with novel chemical processes to visualize molecules in diseased tissues at a scale far beyond conventional methods.

Career

Dardani studied at Villanova University, where he conducted student research on algorithms for water network optimization at the College of Engineering (2011–2013) and on air cooling effectiveness in server hardware (2012). After graduating, he worked as a product development engineer at Unilife Corporation from 2013 to 2015. In 2016, he held a research internship at Cambridge Consultants. He briefly worked as a senior associate at Artisan Healthcare Consulting in 2017 before pursuing graduate studies.

Dardani earned a PhD in Bioengineering from the University of Pennsylvania, where he was a graduate student from 2017 to 2022. He also studied Bioscience Enterprise at the University of Cambridge.

In 2022, Dardani co-founded Biocartesian alongside Jess Li. The company is headquartered in San Francisco and addresses a fundamental limitation in biological research: conventional tools used to study diseased tissues can detect less than 1% of the molecules present in a given sample. Biocartesian's platform integrates microscopy techniques with new chemistries to visualize approximately 50 times more molecules than traditional methods, providing researchers with a significantly more detailed view of the molecular landscape within tissues.

The company's capabilities include spatial profiling of DNA, RNA, and proteins in tissue sections; AI-powered data visualization and segmentation tools with automated analysis workflows; and high-throughput RNA and protein profiling for cell culture applications, including screening services and co-culture model omics. Biocartesian operates in the hard tech, B2B, biotech, diagnostics, and drug discovery sectors.

Biocartesian was accepted into Y Combinator's Summer 2024 batch. As of its YC participation, the company had a team of two people.